Aquestive Therapeutics, Inc. AQST Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s cumulative cost basis?
- Aquestive Therapeutics, Inc. (AQST) reported cumulative cost basis of $47.97M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Aquestive Therapeutics, Inc.'s cumulative cost basis increased by 1.1% year-over-year, from $47.44M to $47.97M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s cumulative cost basis has grown at a 0.1% compound annual growth rate (CAGR), from $47.75M to $47.91M.